Haiwang Bio (000078) Strong Limit-Up Analysis: Performance Evaluation Amid Surge in Flu Demand and Transformation Context

Haiwang Bio (000078) hit a straight limit-up in 3 minutes on November 26, 2025 [3]. The core driving factor is the surge in demand for flu treatment drugs such as chlorpheniramine maleate paracetamol tablets and moroxydine tablets due to the national flu peak season [2]. In addition, the company’s innovative drug pipeline has made significant progress: HW130 injection has started Phase II clinical sample production, and sildenafil orally disintegrating tablets have obtained production approval [1]. In 2024, the controlling shareholder was changed to Silk Textile Group (the actual controller is the People’s Government of Guangdong Province), and the state-owned background brings financing advantages to the company [4]. At the industry level, the pharmaceutical and biological sector showed a differentiation trend in 2025, with innovative drugs and biotech performing well, while pharmaceutical commerce lagged relatively [6]; the company is actively transforming, focusing on medical devices and pharmaceutical industry, and exiting low-margin businesses [8].

Cross-domain correlations show: Short-term flu demand catalysis coexists with long-term transformation strategy; state-owned background support contrasts with fundamental decline; institutional attention is low, but policy benefits (such as innovative drug support policies [1]) provide potential space.

: Net profit in the 2025 third quarter report decreased by 44.39% year-on-year [5], with pressure on fundamentals; low institutional attention [0]. : Demand window during flu peak season; progress in innovative drug pipeline; improvement of financing channels under state-owned background [0].

Haiwang Bio performed strongly in the short term driven by flu demand, but in the long term, attention needs to be paid to the effectiveness of transformation and fundamental improvement. The state-owned background and progress in innovative drugs provide support, but the performance decline and low institutional attention need continuous tracking.